Evidence map›Paper›PMID 34512932›Full record

ArticleJournal of healthcare engineering2021

A PLA2R-IgG4 Antibody-Based Predictive Model for Assessing Risk Stratification of Idiopathic Membranous Nephropathy.

Xiaobin Liu, Jing Xue, Xiaoyi Guo, Yijie Ding, Yi Zhang, Xiran Zhang, Yiqing Huang, Biao Huang, Zhigang Hu, Guoyuan Lu and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of healthcare engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Xiaobin LiuDepartment of Nephrology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Jing XueDepartment of Nephrology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi 214023, China.
Xiaoyi GuoDepartment of Nephrology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi 214023, China.
Yijie DingYangtze Delta Region Institute (Quzhou), University of Electronic Science and Technology of China, Quzhou 324000, China.ORCID 0000-0003-2911-7643
Yi ZhangNHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
Xiran ZhangDepartment of Nephrology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi 214023, China.
Yiqing HuangDepartment of Nephrology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi 214023, China.
Biao HuangCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Zhigang HuMedical Laboratory, The Affiliated Wuxi Children's Hospital of Nanjing Medical University, Wuxi 214023, China.ORCID 0000-0001-5678-2492
Guoyuan LuDepartment of Nephrology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.ORCID 0000-0003-4945-8509
Liang WangDepartment of Nephrology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi 214023, China.ORCID 0000-0002-1456-4718
Wuxi People's Hospital · CNSoochow University · CNKey Laboratory of Nuclear Radiation and Nuclear Energy Technology · CNSecond Affiliated Hospital of Nanjing Medical University · CNUniversity of Electronic Science and Technology of China · CNZhejiang Sci-Tech University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Known as an autoimmune glomerular disease, idiopathic membranous nephropathy (IMN) is considered to be associated with phospholipase A2 receptor (PLA2R) in terms of the main pathogenesis. The quantitative detection of serum PLA2R-IgG and PLA2R-IgG4 antibodies by time-resolved fluoroimmunoassay (TRFIA) was determined, and the value of them, both in the clinical prediction of risk stratification in IMN, was observed in this study. Methods: 95 patients with IMN proved by renal biopsy were enrolled, who had tested positive for serum PLA2R antibodies by ELISA, and the quantitative detection of serum PLA2R-IgG and PLA2R-IgG4 antibodies was achieved by TRFIA. All the patients were divided into low-, medium-, and high-risk groups, respectively, which were set as dependent variables, according to proteinuria and renal function. Random forest (RF) was used to estimate the value of serum PLA2R-IgG and PLA2R-IgG4 in predicting the risk stratification of progression in IMN. Results: Out-of-bag estimates of variable importance in RF were employed to evaluate the impact of each input variable on the final classification accuracy. The variable of albumin, PLA2R-IgG, and PLA2R-IgG4 had high values (>0.3) of 0.3156, 0.3981, and 0.7682, respectively, which meant that these three were more important for the risk stratification of progression in IMN. In order to further assess the contribution of PLA2R-IgG and PLA2R-IgG4 to the model, we built four different models and found that PLA2R-IgG4 played an important role in improving the predictive ability of the model. Conclusions: In this study, we established a random forest model to evaluate the value of serum PLA2R-IgG4 antibodies in predicting risk stratification of IMN. Compared with PLA2R-IgG, PLA2R-IgG4 is a more efficient biomarker in predicting the risk of progression in IMN.

Indexed as

Glomerulonephritis, MembranousReceptors, Phospholipase A2BiomarkersHumansImmunoglobulin GRisk AssessmentBiomarkersImmunoglobulin GReceptors, Phospholipase A2

Identifiers

PMID34512932
PMCPMC8424241
OpenAlexW3198621954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.